Literature DB >> 23406305

Prospective isolation of mesenchymal stem cells from human bone marrow using novel antibodies directed against Sushi domain containing 2.

Kavitha Sivasubramaniyan1, Abhishek Harichandan, Susanne Schumann, Malgorzata Sobiesiak, Claudia Lengerke, Andreas Maurer, Hubert Kalbacher, Hans-Jörg Bühring.   

Abstract

Several strategies have been developed to facilitate the prospective isolation of bone marrow-derived mesenchymal stem/stromal cells (BM-MSCs) based on the selective expression or absence of surface markers. Recently, we described the monoclonal antibodies W3D5 and W5C5, which selectively react with BM-MSCs, but not with hematopoietic cells. Both antibodies showed an identical reactivity pattern, indicating that they may recognize the same molecule. To identify the cognate antigen, cultured MSCs were sorted for cells expressing either very high levels of W5C5/W3D5 antigen or for cells which were negative for this antigen. Further processing of these cells for microarray analysis revealed a 20-fold enrichment of the type 1 integral membrane protein Sushi domain containing 2 (SUSD2) in the in W5C5(+) subset. To confirm the identity of the W5C5/W3D5 antigen to SUSD2, HEK293 cells were transfected with the full-length coding sequence of human SUSD2 followed by reactivity analysis of W5C5 and W3D5 antibodies with the transfected line. Flow cytometric analysis showed that both antibodies selectively recognized HEK293/huSUSD2 cells, but not the parental cell line. In line with this, SUSD2 siRNA treatment of SUSD2(+) WERI-RB-1 retinoblastoma cells reduced the expression levels of W3D5 and W5C5 antigens to ~39% and 37%, respectively. Finally, FACSorting and colony assays revealed that only SUSD2(+), but not SUSD2(-) BM cells give rise to colony-forming units-fibroblasts and are able to differentiate into osteoblasts, adipocytes, and chondrocytes. In conclusion, we identified SUSD2 as a novel and specific marker for the prospective isolation of BM-MSCs.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23406305     DOI: 10.1089/scd.2012.0584

Source DB:  PubMed          Journal:  Stem Cells Dev        ISSN: 1547-3287            Impact factor:   3.272


  27 in total

1.  Expression of stage-specific embryonic antigen-4 (SSEA-4) defines spontaneous loss of epithelial phenotype in human solid tumor cells.

Authors:  Kavitha Sivasubramaniyan; Abhishek Harichandan; Karin Schilbach; Andreas F Mack; Jens Bedke; Arnulf Stenzl; Lothar Kanz; Gerhard Niederfellner; Hans-Jörg Bühring
Journal:  Glycobiology       Date:  2015-05-15       Impact factor: 4.313

Review 2.  Identification and Characterization of Human Endometrial Mesenchymal Stem/Stromal Cells and Their Potential for Cellular Therapy.

Authors:  Saeedeh Darzi; Jerome A Werkmeister; James A Deane; Caroline E Gargett
Journal:  Stem Cells Transl Med       Date:  2016-05-31       Impact factor: 6.940

Review 3.  Endometrial mesenchymal stem cells as a cell based therapy for pelvic organ prolapse.

Authors:  Stuart J Emmerson; Caroline E Gargett
Journal:  World J Stem Cells       Date:  2016-05-26       Impact factor: 5.326

4.  Putative human myometrial and fibroid stem-like cells have mesenchymal stem cell and endometrial stromal cell properties.

Authors:  Amanda L Patterson; Jitu W George; Anindita Chatterjee; Tyler J Carpenter; Emily Wolfrum; David W Chesla; Jose M Teixeira
Journal:  Hum Reprod       Date:  2020-01-01       Impact factor: 6.918

5.  Low osteogenic differentiation potential of placenta-derived mesenchymal stromal cells correlates with low expression of the transcription factors Runx2 and Twist2.

Authors:  Christine Ulrich; Bernd Rolauffs; Harald Abele; Michael Bonin; Kay Nieselt; Melanie L Hart; Wilhelm K Aicher
Journal:  Stem Cells Dev       Date:  2013-07-20       Impact factor: 3.272

6.  Identification and characterisation of maternal perivascular SUSD2+ placental mesenchymal stem/stromal cells.

Authors:  Fiona L Cousins; Caroline E Gargett; Manijeh Khanmohammadi; Shayanti Mukherjee; Saeedeh Darzi; Kallyanashis Paul; Jerome A Werkmeister
Journal:  Cell Tissue Res       Date:  2021-05-07       Impact factor: 5.249

Review 7.  Allogenic Use of Human Placenta-Derived Stromal Cells as a Highly Active Subtype of Mesenchymal Stromal Cells for Cell-Based Therapies.

Authors:  Raphael Gorodetsky; Wilhelm K Aicher
Journal:  Int J Mol Sci       Date:  2021-05-18       Impact factor: 5.923

Review 8.  Stem Cell-Based Therapy for Asherman Syndrome: Promises and Challenges.

Authors:  Yiyin Gao; Guijie Wu; Ying Xu; Donghai Zhao; Lianwen Zheng
Journal:  Cell Transplant       Date:  2021 Jan-Dec       Impact factor: 4.064

9.  Examining the feasibility of clinical grade CD271+ enrichment of mesenchymal stromal cells for bone regeneration.

Authors:  Richard J Cuthbert; Peter V Giannoudis; Xiao N Wang; Lindsay Nicholson; David Pawson; Anatole Lubenko; Hiang B Tan; Anne Dickinson; Dennis McGonagle; Elena Jones
Journal:  PLoS One       Date:  2015-03-11       Impact factor: 3.240

Review 10.  Where is the common ground between bone marrow mesenchymal stem/stromal cells from different donors and species?

Authors:  Elena Jones; Richard Schäfer
Journal:  Stem Cell Res Ther       Date:  2015-08-18       Impact factor: 6.832

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.